Lexaria Bioscience - Warrants (11/01/2026) Profit Margin

Lexaria Bioscience - Warrants (11/01/2026) posts a profit margin of -3985.58% as of May 2026. That compares with -1849.39% in the prior-year period — down 115.5% year over year. That is below the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Lexaria Bioscience - Warrants (11/01/2026)'s profit margin was -1849.39%. The latest reading is -3985.58% — a 115.5% year-over-year decrease (period ending May 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Lexaria Bioscience - Warrants (11/01/2026)'s -3985.58% is lower that level. That is roughly 28787.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Lexaria Bioscience - Warrants (11/01/2026)'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -3985.58% as of May 2026; use YoY and peer views to separate noise from signal.

Context for LEXXW's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Lexaria Bioscience - Warrants (11/01/2026)'s other metric pages and overview cover the third.